

FILE 'STNGUIDE' ENTERED AT 13:03:08 ON 19 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jan 14, 2005 (20050114/UP).

=> FIL HOME

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	0.27

FILE 'HOME' ENTERED AT 13:03:14 ON 19 JAN 2005

=> file biosis bioscience dissabs

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.48

FILE 'BIOSIS' ENTERED AT 13:03:34 ON 19 JAN 2005
Copyright (c) 2005 The Thomson Corporation.

FILE 'ADISCTI' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 13:03:34 ON 19 JAN 2005

FILE 'ANABSTR' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (c) 2005 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'AQUALINE' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT 2005 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 13:03:34 ON 19 JAN 2005
Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOENG' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 13:03:34 ON 19 JAN 2005

COPYRIGHT (C) 2005 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 13:03:34 ON 19 JAN 2005

FILE 'CAPLUS' ENTERED AT 13:03:34 ON 19 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (c) 2005 DECHEMA eV

FILE 'CEN' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 13:03:34 ON 19 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'CROPU' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DDFB' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DRUGB' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 13:03:34 ON 19 JAN 2005

FILE 'FOMAD' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 International Food Information Service

FILE 'GENBANK' ENTERED AT 13:03:34 ON 19 JAN 2005

FILE 'HEALSAFE' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (c) 2005 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 13:03:34 ON 19 JAN 2005

FILE 'NIOSH TIC' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 13:03:34 ON 19 JAN 2005
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2005)

FILE 'NUTRACEUT' ENTERED AT 13:03:34 ON 19 JAN 2005
Copyright 2005 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 13:03:34 ON 19 JAN 2005
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2005 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 WIPO

FILE 'PHAR' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 13:03:34 ON 19 JAN 2005
Copyright 2005 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Prous Science

FILE 'PS' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Thieme on STN

FILE 'RDISCLOSURE' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 13:03:34 ON 19 JAN 2005
Copyright (c) 2005 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Prous Science

FILE 'TOXCENTER' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 ACS

FILE 'USPATFULL' ENTERED AT 13:03:34 ON 19 JAN 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:03:34 ON 19 JAN 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPIFV' ENTERED AT 13:03:34 ON 19 JAN 2005
COPYRIGHT (C) 2005 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s (skin or hair) (s) (human (w) serum (w) albumin) and cosmetic?

L1	0 FILE BIOSIS
L2	0 FILE ADISCTI
L3	0 FILE ADISINSIGHT
L4	0 FILE ADISNEWS
L5	0 FILE AGRICOLA
L6	0 FILE ANABSTR
L7	0 FILE ANTE
L8	0 FILE AQUALINE
L9	0 FILE AQUASCI
L10	0 FILE BIOBUSINESS
L11	0 FILE BIOCOMMERCE
L12	0 FILE BIOENG

L13	2	FILE BIOTECHDS
L14	0	FILE BIOTECHNO
L15	0	FILE CABA
L16	0	FILE CANCERLIT
L17	6	FILE CAPLUS
L18	0	FILE CEABA-VTB
L19	0	FILE CEN
L20	0	FILE CIN
L21	0	FILE CONFSCI
L22	0	FILE CROPB
L23	0	FILE CROPU
L24	0	FILE DDFB
L25	20	FILE DGENE
L26	0	FILE DISSABS
L27	0	FILE DRUGB
L28	0	FILE DRUGMONOG2
L29	1	FILE DRUGU
L30	0	FILE EMBAL
L31	0	FILE EMBASE
L32	0	FILE ESBIODASE

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'HAIR) (S) '

L33	0	FILE FEDRIP
L34	0	FILE FOMAD
L35	0	FILE FOREGE
L36	0	FILE FROSTI
L37	0	FILE FSTA
L38	0	FILE GENBANK
L39	0	FILE HEALSAFE
L40	1	FILE IFIPAT
L41	0	FILE IMSDRUGNEWS
L42	0	FILE IMSPRODUCT
L43	0	FILE IMSRESEARCH
L44	0	FILE JICST-EPLUS
L45	0	FILE KOSMET
L46	1	FILE LIFESCI
L47	0	FILE MEDICONF
L48	0	FILE MEDLINE
L49	0	FILE NIOSHTIC
L50	0	FILE NTIS
L51	0	FILE NUTRACEUT
L52	0	FILE OCEAN
L53	2	FILE PASCAL
L54	0	FILE PCTGEN
L55	0	FILE PHAR
L56	0	FILE PHARMAML
L57	0	FILE PHIC
L58	0	FILE PHIN
L59	1	FILE PROMT
L60	0	FILE PROUSDDR
L61	0	FILE PS
L62	0	FILE RDISCLOSURE
L63	0	FILE SCISEARCH
L64	0	FILE SYNTHLINE
L65	0	FILE TOXCENTER
L66	15	FILE USPATFULL
L67	0	FILE USPAT2
L68	0	FILE VETB
L69	0	FILE VETU
L70	0	FILE WATER
L71	6	FILE WPIDS
L72	0	FILE WPIFV

TOTAL FOR ALL FILES

L73	55	(SKIN OR HAIR) (S) (HUMAN (W) SERUM (W) ALBUMIN) AND COSMETIC?
-----	----	--

=> dup rem l73

DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE, DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'. ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L73

L74 47 DUP REM L73 (8 DUPLICATES REMOVED)

=> d l74 1-47 ibib abs

L74 ANSWER 1 OF 47 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
DUPLICATE 1

ACCESSION NUMBER: 2004-06830 BIOTECHDS

TITLE: Preparing a fusion polypeptide comprising epidermal growth factor and human serum albumin in a plant comprises transforming plant cells with a polynucleotide sequence that encodes the fusion polypeptide;
vector-mediated fusion gene transfer and expression in transgenic plant for recombinant protein production and disease therapy

AUTHOR: LEE S; YOO J; PARK S

PATENT ASSIGNEE: NEXGEN BIOTECHNOLOGIES INC

PATENT INFO: WO 2004005520 15 Jan 2004

APPLICATION INFO: WO 2003-KR1310 2 Jul 2003

PRIORITY INFO: KR 2002-38165 3 Jul 2002; KR 2002-38165 3 Jul 2002

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: WPI: 2004-091372 [09]

AN 2004-06830 BIOTECHDS

AB DERWENT ABSTRACT:

NOVELTY - Preparing a fusion polypeptide comprising epidermal growth factor (EGF) and **human serum albumin** in a plant comprising transforming plant cells with a polynucleotide sequence comprising a sequence that encodes the fusion polypeptide, a promoter, and a 3'-non-translated region, is new.

DETAILED DESCRIPTION - Preparing a fusion polypeptide comprising epidermal growth factor (EGF) and **human serum albumin** in a plant comprising transforming plant cells with a polynucleotide sequence comprising a sequence that encodes the fusion polypeptide, a promoter, and a 3'-non-translated region, comprising: (a) transforming plant cells with a polynucleotide sequence comprising a nucleotide sequence encoding the fusion polypeptide comprising EGF and **human serum albumin** linked to the C-terminal or N-terminal of the EGF, where the stability of the EGF is enhanced by virtue of the **human serum albumin**; a promoter that functions in plant cells to cause the production of an RNA molecule operably linked to the nucleotide sequence; and a 3'-non-translated region that functions in plant cells to cause the polyadenylation of the 3'-end of the RNA molecule; (b) selecting transformed plant cells; (c) regenerating a plant from the transformed cells; and (d) recovering the fusion polypeptide from the regenerated plant.

WIDER DISCLOSURE - The following are also disclosed as new: (1) a nucleotide sequence encoding the fusion polypeptide; (2) an expression vector comprising the nucleotide sequence; (3) a **cosmetic** composition for **skin** care; and (4) a pharmaceutical composition.

BIOTECHNOLOGY - Preferred Plant: In preparing a fusion polypeptide, the plant is *Nicotiana tabacum*, *Cucumis melo*, *Cucumis sativa*, *Citrullus vulgaris*, or *Brassica campestris*. Preferred Nucleic Acid: The nucleotide sequence of the EGF comprises nucleotide 1-159 of a sequence of 165 amino acids fully defined in the specification. Preferred Fusion Protein: The **human serum albumin** is linked to the C-terminal of the EGF. Preferred Method: The method alternatively comprises: (a) inoculating an explant material from the plant with *Agrobacterium tumefaciens* harboring a vector that is capable of inserting

into a genome of cell from the plant and containing the nucleotide sequence cited above; (b) regenerating the inoculated explant material on a regeneration medium to obtain regenerated shoots; (c) culturing the regenerated shoots on a rooting medium to obtain a transformed plant, where the transformed plant is capable of expressing the nucleotide sequence; and (d) recovering the fusion polypeptide from the transformed plant.

ACTIVITY - Gastrointestinal-Gen.; Antiulcer; Antiparkinsonian; Dermatological; Vulnerary. No biological data given.

MECHANISM OF ACTION - Protein Therapy. No biological data given.

USE - The method is useful for preparing a fusion polypeptide comprising epidermal growth factor and **human serum albumin** in plant (claimed). The fusion polypeptide is useful for preparing a **cosmetic** composition for **skin** care, and a pharmaceutical composition for treating, e.g. gastric ulcers, neurodegenerative disorders such as Parkinson's disease and wound healing.

ADMINISTRATION - Dosage is 0.001-100 mg/kg. Administration is oral, parenteral or topical.

EXAMPLE - Escherichia coli BL21 (DE3) transformed with Albumin-EGF/pET28alpha was cultured to OD650 0.5 in 5 liter fermenter and the expression of the fused gene was then induced by addition of 0.5 mM IPTG. Following additional culture for 5-6 hours, the cells were collected by centrifugation. The collected cells were completely suspended in 40 ml of buffer, disrupted by ultrasonification, centrifuged and the resulting supernatant was then collected. The supernatant was electrophoresed pm 8 % polyacrylamide gel to verify the expression of the fusion protein. The supernatant was applied to Ni-agarose column activated with a binding buffer and passed at a rate of 1-3 ml/minute. Then, using the binding buffer, the column was washed and each of 20, 40, 60, 100, 300 and 500 nM imidazole solutions was applied to the column in stepwise manner, finally eluting the fusion protein. (57 pages)

L74 ANSWER 2 OF 47 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
DUPLICATE 2

ACCESSION NUMBER: 2004-06841 BIOTECHDS

TITLE: Novel fusion polypeptide having epidermal growth factor and human serum albumin linked to C-terminal or N-terminal of epidermal growth factor in which stability of growth factor is enhanced by human serum albumin;
vector-mediated fusion gene transfer and expression in host cell for recombinant protein production and **cosmetic** manufacture

AUTHOR: LEE S; YOO J; PARK S

PATENT ASSIGNEE: NEXGEN BIOTECHNOLOGIES INC

PATENT INFO: WO 2004005340 15 Jan 2004

APPLICATION INFO: WO 2003-KR1309 2 Jul 2003

PRIORITY INFO: KR 2002-38165 3 Jul 2002; KR 2002-38165 3 Jul 2002

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: WPI: 2004-099372 [10]

AN 2004-06841 BIOTECHDS

AB DERWENT ABSTRACT:

NOVELTY - A fusion polypeptide (I) comprising epidermal growth factor (EGF) and **human serum albumin** linked to the C-terminal or N-terminal of the EGF, and in which the stability of the EGF is enhanced by virtue of the **human serum albumin**, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following: (1) a nucleotide sequence (II) encoding a fusion polypeptide comprising EGF and **human serum albumin** linked to the C-terminal or N-terminal of the EGF; (2) an expression vector (III) comprising (II) and a promoter operably linked to the nucleotide sequence; (3) a transformant (IV) comprising (III); (4) preparing (I); (5) a **cosmetic** composition for **skin** care, which comprises a fusion polypeptide comprising EGF and

human serum albumin linked to the C-terminal or N-terminal of the EGF as an active ingredient and a carrier; and (6) a pharmaceutical composition (P1), comprising a fusion polypeptide comprising EGF and human serum albumin linked to the C-terminal or N-terminal of the EGF as an active ingredient and a carrier.

BIOTECHNOLOGY - Preparation: Preparing (I) involves culturing (IV) under conditions for expression and recovering (I) (claimed). Preferred Polypeptide: In (I), the human serum albumin is linked to C-terminal of EGF. Preferred Nucleotide: In (II), a nucleotide sequence coding for the human serum albumin is linked to the 3' end of the EGF. The nucleotide sequence coding for EGF comprises a sequence (S1) of 159 nucleotides, given in the specifications. Preferred Vector: In (III), a nucleotide sequence of EGF comprises (S1). Preferred Transformant: (IV) is a bacterium, fungus, plant cell or animal cell.

USE - (I) is useful for preparing cosmetic composition for skin care.

ADMINISTRATION - (I) is administered through oral, parenteral or topical route. Dosage ranges from 0.001-100 mg/kg.

ADVANTAGE - (I) has higher stability and purity.

EXAMPLE - To amplify the epidermal growth factor (EGF) gene, PCR amplification was performed using the EGF gene as template and a pair of primers designed to introduce BamHI and HindIII recognition sites into 5'- and 3'- termini of the gene, respectively. The nucleotide sequences of primers are: reverse primer 5'-CCCAAGCTTTCAGCGCAGTCCCACCACTT-3' and forward primer 5'-CGGGATCCAACAGCGATTTCAGAAATGTCCAC-3'. The PCR product was digested with BamHI and HindIII and extracted. The EGF gene extracted and purified was ligated to pUC18 and digested with BamHI and HindIII using T4 DNA ligase. The resulting vector was transformed into CaCl2-treated Escherichia coli DH5alpha and then the transformed cells with ampicillin resistance were selected by culturing in Luria Broth (LB) medium containing ampicillin (100 mg/ml). The cloned plasmids (EGF/pUC18) were isolated from the transformed cells. PCR amplification was performed using cDNA of human serum albumin as template and a pair of primers designed to introduce EcoRI and BamHI recognition sites into 5'- and 3'- termini of the gene, respectively. The nucleotide sequences of primers are: reverse primer 5'-CGGGATCCACCGGTACGCGTAGAATCGAGACC-3' and forward primer 5'-CGGAATTCATGAAGTGGGTAACCTTTATTTCC-3'. The PCR product was digested with EcoRI and BamHI and extracted. The human serum albumin gene extracted and purified was ligated to EGF/pUC18 digested with EcoRI and BamHI using T4 DNA ligase. The resulting plasmid was introduced into CaCl2-treated E. coli DH5alpha and then the transformed cells with ampicillin resistance were selected by culturing in LB medium containing ampicillin (100 mg/ml). The cloned plasmids (Albumin-EGF/pUC18) were isolated from the transformed cells. Following the digestion of Albumin-EGF/pUC18 plasmid with EcoRI and HindIII, the resultant was subjected to electrophoresis on agarose gel and the albumin-EGF fusion gene was extracted and purified. (57 pages)

L74 ANSWER 3 OF 47 USPATFULL on STN

ACCESSION NUMBER: 2004:221354 USPATFULL

TITLE: ALBUMIN FUSION PROTEINS

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004171123	A1	20040902
APPLICATION INFO.:	US 2001-832929	A1	20010412 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP,		
	1300 I STREET, NW, WASHINGTON, DC, 20005		
NUMBER OF CLAIMS:	29		

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 17424
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 4 OF 47 USPATFULL on STN

ACCESSION NUMBER: 2004:184164 USPATFULL

TITLE: Korean acanthopanax senticosus extract, protein extract, crude protein-polysaccharide which were extracted from korean acanthopanax senticosus, and immunoregulating compositions comprising the same and use thereof

INVENTOR(S): Yoon, Taek-Joon, Kyungki-do, KOREA, REPUBLIC OF
Lee, Kyeong-Ho, Kyungki-do, KOREA, REPUBLIC OF
Park, Woo-Moon, Seoul, KOREA, REPUBLIC OF
Kim, Youn-Chul, Kyungki-do, KOREA, REPUBLIC OF
Park, Ho-Jin, Kyungki-do, KOREA, REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004142047	A1	20040722
APPLICATION INFO.:	US 2003-478009	A1	20031117 (10)
	WO 2002-KR1036		20020531

	NUMBER	DATE
PRIORITY INFORMATION:	KR 2001-30999	20010602
	KR 2001-74244	20011127
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	1462	

AB The present invention relates to a Korean Acanthopanax Senticosus extract, a protein extract and crude protein polysaccharide derived therefrom, and an immuno-regulating composition comprising the same as an active ingredient and the use thereof, and more particularly to a Korean Acanthopanax Senticosus extract and a protein extract and crude protein polysaccharide derived therefrom, which are have effective in increasing immunity and have superior anti-allergy effects and thus can be used as an active ingredient for functional foods, cosmetics, and pharmaceutical compositions, and as an immuno-regulating compositoin comprising the same as an active ingredient and the use thereof.

L74 ANSWER 5 OF 47 USPATFULL on STN

ACCESSION NUMBER: 2004:13611 USPATFULL

TITLE: Albumin fusion proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	25066	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 6 OF 47 USPATFULL on STN
 ACCESSION NUMBER: 2003:312278 USPATFULL
 TITLE: Albumin fusion proteins
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	15415	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or

ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 7 OF 47 USPATFULL on STN

ACCESSION NUMBER: 2003:282700 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES
Sleep, Darrell, West Bridgford, UNITED KINGDOM
Prior, Christopher P., Rosemont, PA, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023
APPLICATION INFO.:	US 2001-832501	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	60	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	14339	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 8 OF 47 USPATFULL on STN

ACCESSION NUMBER: 2003:244853 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Prior, Christopher P., Rosemont, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171267	A1	20030911
APPLICATION INFO.:	US 2001-833117	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 59

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 20 Drawing Page(s)

LINE COUNT: 13208

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 9 OF 47 USPATFULL on STN

ACCESSION NUMBER: 2003:200476 USPATFULL

TITLE: Methods of treating animals with botulinum toxin
pharmaceutical compositions

INVENTOR(S): Hunt, Terrence J., Corona, CA, UNITED STATES

PATENT ASSIGNEE(S): Allergan, Inc (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003138460	A1	20030724
APPLICATION INFO.:	US 2003-360098	A1	20030207 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-47058, filed on 14 Jan 2002, PENDING Continuation-in-part of Ser. No. US 2000-500147, filed on 8 Feb 2000, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	STEPHEN DONOVAN, ALLERGAN, INC., 2525 Dupont Drive, T2-7H, Irvine, CA, 92612		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2175		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for treating animals, such as mammals and birds with a botulinum toxin comprising administering at least one serotype of a botulinum toxin to the animal. The botulinum toxin can be administered in a composition having a polysaccharide that stabilizes the botulinum toxin. The compositions administered to the animals have reduced immunogenicity, and are preferably non-immunogenic and/or have a reduced toxicity. The methods may also be practiced with recombinant, or species-specific, serum albumins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 10 OF 47 USPATFULL on STN

ACCESSION NUMBER: 2003:200454 USPATFULL

TITLE: Reduced toxicity clostridial toxin pharmaceutical
compositions

INVENTOR(S): Hunt, Terrence J., Corona, CA, UNITED STATES

PATENT ASSIGNEE(S): Allergan, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003138437	A1	20030724
APPLICATION INFO.:	US 2003-359828	A1	20030207 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-288738, filed on 5 Nov 2002, PENDING Continuation-in-part of Ser. No.		

US 2002-47058, filed on 14 Jan 2002, PENDING
Continuation-in-part of Ser. No. US 2000-500147, filed
on 8 Feb 2000, PENDING

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN DONOVAN, ALLERGAN, INC., 2525 Dupont Drive,
T2-7H, Irvine, CA, 92612
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 2295

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A Clostridial toxin pharmaceutical composition comprising a Clostridial toxin, such as a botulinum toxin and a polysaccharide, such as a hydroxyethyl starch, wherein the pharmaceutical composition has a reduced toxicity. The Clostridial toxin pharmaceutical composition can be essentially free of any blood or serum derived proteins, filtrates or fractions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 11 OF 47 USPATFULL on STN

ACCESSION NUMBER: 2003:181414 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703
APPLICATION INFO.:	US 2001-833041	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 15235

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 12 OF 47 LIFESCI COPYRIGHT 2005 CSA on STN DUPLICATE 3

ACCESSION NUMBER: 2003:83199 LIFESCI
TITLE: An assessment of the phototoxic hazard of a personal product ingredient using in vitro assays
AUTHOR: Jones, P.A.; King, A.V.; Earl, L.K.; Lawrence, R.S.
CORPORATE SOURCE: Safety and Environmental Assurance Centre, Unilever
Colworth, Sharnbrook, Bedfordshire MK44 1LQ, UK; E-mail:
penny.jones@unilever.com

SOURCE: Toxicology In Vitro [Toxicol. In Vitro], (20030800) vol. 17, no. 4, pp. 471-480.
ISSN: 0887-2333.

DOCUMENT TYPE: Journal

FILE SEGMENT: X

LANGUAGE: English

SUMMARY LANGUAGE: English

AB Where substances are intended for use in personal products applied to the **skin** an assessment of potential phototoxic hazard is required. This report describes a tiered testing strategy involving in vitro assays used for the phototoxic hazard assessment of a personal product ingredient (Ingredient X). The initial assay was measurement of a UV/visible absorption spectrum to identify absorption at relevant wavelengths. This was followed by in vitro assays for phototoxicity (3T3 cell neutral red uptake phototoxicity test) and photoallergy (photobinding to **human serum albumin**). These in vitro screens gave equivocal results for Ingredient X which appeared to suggest a weak phototoxic reaction. To further evaluate the phototoxic hazard of Ingredient X to **human skin**, a phototoxicity assay using a 3-D human **skin** model was conducted. Ingredient X did not cause phototoxicity in this assay. Overall conclusions from these studies were that although Ingredient X showed slight intrinsic potential for photoactivation, it was unlikely to present a hazard to **human skin**. This report illustrates the value in a step-wise strategy of the use of **human skin** models to help interpret the results of other in vitro phototoxicity assays.

L74 ANSWER 13 OF 47 PASCAL COPYRIGHT 2005 INIST-CNRS. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 2004-0103292 PASCAL

COPYRIGHT NOTICE: Copyright .COPYRGT. 2004 INIST-CNRS. All rights reserved.

TITLE (IN ENGLISH): Specific immunoglobulin E in patients with immediate persulfate hypersensitivity

AUTHOR: AALTO-KORTE Kristiina; MAEKINEN-KILJUNEN Soili

CORPORATE SOURCE: Division of Dermatology and Venereology, Helsinki, Finland; Division of Allergology, Helsinki University Central Hospital, Skin and Allergy Hospital, Helsinki, Finland

SOURCE: Contact dermatitis, (2003), 49(1), 22-25, 18 refs.
ISSN: 0105-1873 CODEN: CODEDG

DOCUMENT TYPE: Journal

BIBLIOGRAPHIC LEVEL: Analytic

COUNTRY: United Kingdom

LANGUAGE: English

AVAILABILITY: INIST-16783, 354000116024560040

AN 2004-0103292 PASCAL

CP Copyright .COPYRGT. 2004 INIST-CNRS. All rights reserved.

AB Persulfate salts may cause contact urticaria, allergic and irritant contact dermatitis, rhinitis and asthma. The mechanism of the immediate reactions has been unclear. Positive prick test, **skin** application and nasal and bronchial provocations identify immediate allergy. There is only 1 previous report of specific binding of immunoglobulin E (IgE) to ammonium persulfate demonstrated by radioallergosorbent test (RAST). In the present study, fresh 2% ammonium and potassium persulfate solutions were used for prick testing. Patients with positive prick tests were further evaluated with open **skin** application, immunospot and RAST. Prick testing with persulfate salts was performed in a total of 138 patients. 7 patients had a positive reaction to at least 1 persulfate salt. 6 of the patients had had **skin** symptoms, urticaria, eczema or angioedema, because of contact with **hair bleaches**. Open application on healthy **skin** was performed in 4 patients, and 3 out of them had urticarial reactions. The sera of 5 patients were investigated with immunospot and RAST. On immunospot, specific binding of IgE to **human serum albumin** (HSA)-conjugated ammonium and potassium persulfate was

found in 2 patients. 1 immunospot-positive patient also had a positive RAST to ammonium persulfate-HSA conjugate. The mechanism of immediate hypersensitivity to persulfates thus seems to be IgE-mediated at least in some patients.

L74 ANSWER 14 OF 47 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2002:51973 CAPLUS

DOCUMENT NUMBER: 136:107250

TITLE: Serum albumin compositions for use in cleansing or dermatological products for skin or hair

INVENTOR(S): Carter, Daniel C.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 5 pp., Cont.-in-part of U. S. Ser. No. 616,962.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002006892	A1	20020117	US 2000-740821	20001221
US 6787636	B1	20040907	US 2000-616962	20000714
WO 2002049671	A1	20020627	WO 2001-US48820	20011221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002030967	A5	20020701	AU 2002-30967	20011221
EP 1353698	A1	20031022	EP 2001-991225	20011221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.:
 US 2000-616962 A2 20000714
 US 2000-740821 A 20001221
 WO 2001-US48820 W 20011221

AB A hypoallergenic cleansing, **cosmetic**, conditioning or dermatol. composition for treating skin or hair is provided which contains serum albumin in an amount effective to achieve cleansing, conditioning, wound debridement, or other beneficial **cosmetic** or dermatol. purpose for skin or hair, along with a suitable cleansing, conditioning, **cosmetic**, antibacterial or dermatol. agent, vehicle, carrier or excipient. The compns. may be in any suitable form for treating skin or hair, such as a soap, shampoo, cream, oil, lotion, gel, gel-based ointment, and the like. The serum albumin compns. are preferably prepared using **human serum albumin** produced by recombinant means, and such compns. are useful in that they allow the albumin to be absorbed in the surface of **skin** or **hair** so as to replenish the structure of these tissues when utilized as a cleansing, **cosmetic** or dermatol. agent. The compns. of the present invention will provide cleansing, **cosmetic** or dermatol. compns. that can be used safely and effectively with reduced likelihood of allergic reaction.

L74 ANSWER 15 OF 47 USPATFULL on STN

ACCESSION NUMBER: 2002:227878 USPATFULL

TITLE: METHODS OF USE OF COMPOUNDS WHICH INHIBIT THE STEM CELL SIGNALING PATHWAY

INVENTOR(S): LONGLEY, B. JACK, HAMDEN, CT, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2002123031 A1 20020905
 APPLICATION INFO.: US 1999-474478 A1 19991229 (9)
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-306143, filed
 on 6 May 1999, PENDING
 DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: JOHN P WHITE, COOPER & DUNHAM LLP, 1185 AVENUE OF THE
 AMERICAS, NEW YORK, NY, 10036
 NUMBER OF CLAIMS: 38
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 9 Drawing Page(s)
 LINE COUNT: 1257
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a method of preventing or treating in a subject
 contact dermatitis which comprises administering to the subject an
 amount of a compound capable of inhibiting the stem cell factor
 signaling pathway effective to prevent or treat contact dermatitis so as
 to thereby prevent or treat contact dermatitis in the subject. This
 invention also provides a methods of preventing or treating in a subject
 hyperpigmentation, asthma, cutaneous inflammation, anaphylaxis and
 bronchospasm, mastocytosis, tumors which express activated kit, and
 conception.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 16 OF 47 USPATFULL on STN
 ACCESSION NUMBER: 2002:95768 USPATFULL
 TITLE: Method for promoting hair growth
 INVENTOR(S): Kubo, Michinori, Sakai, JAPAN
 Yoshikawa, Masayuki, Minoo, JAPAN
 Matsuda, Hideaki, Habikino, JAPAN
 Matsuda, Hisashi, Kyoto, JAPAN
 Murakami, Toshiyuki, Kyoto, JAPAN
 Shimada, Hiromi, Toyonaka, JAPAN
 Sakurama, Tetsuo, Osaka, JAPAN
 Nomura, Manabu, Miyazaki, JAPAN
 PATENT ASSIGNEE(S): Nomura Co., Ltd., Miyazaki, JAPAN (non-U.S.
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6380168	B1	20020430
APPLICATION INFO.:	US 2000-611422		20000707 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-30732, filed on 25 Feb 1998, now patented, Pat. No. US 6297363 Continuation-in-part of Ser. No. US 1996-661970, filed on 12 Jun 1996, now patented, Pat. No. US 5750107 Continuation-in-part of Ser. No. US 167828, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-113304	19970325
	JP 1997-113305	19970325
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Prats, Francisco	
LEGAL REPRESENTATIVE:	Sheridan Ross P.C.	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	424	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a composition which is useful for
 promoting hair growth and methods for using the same. The hair growth

promoter composition comprises a compound of the formula: ##STR1##

wherein X, R.sub.1, R.sub.2, Z.sub.1, and Z.sub.2 are those described herein. Preferably, the compound comprises at least two saccharide moieties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 17 OF 47 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 2003-334169 [32] WPIDS
DOC. NO. CPI: C2003-086934
TITLE: Wrinkle-eliminating **cosmetics** are prepared with type-A botulinus toxin, azone and physiological saline, vitamin E, alpha-AHAS, SOD as well as protector and human serum albumin.
DERWENT CLASS: B04 B05 D21
INVENTOR(S): LU, W; SHENG, Q
PATENT ASSIGNEE(S): (LUWW-I) LU W
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
CN 1383811	A	20021211	(200332)*		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
CN 1383811	A	CN 2002-111695	20020516

PRIORITY APPLN. INFO: CN 2002-111695 20020516

AN 2003-334169 [32] WPIDS

AB CN 1383811 A UPAB: 20030522

NOVELTY - Wrinkle-eliminating **cosmetics** are prepared with type-A botulinus toxin, azone and physiological saline, vitamin E, alpha-AHAS, SOD as well as protector and **human serum albumin**. The production process includes mixing of the components and diluting the mixture with physiological saline. The composition has the effect of palsying neuromuscular junction to reduce tonus muscle, remit cramp, stretch **skin** and eliminate wrinkles.
Dwg.0/0

L74 ANSWER 18 OF 47 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:885699 CAPLUS

DOCUMENT NUMBER: 136:10945

TITLE: **Cosmetic** composition comprising human serum albumin obtained from transgenic non-human animals
INVENTOR(S): Eichner, Wolfram; Sommermeyer, Klaus
PATENT ASSIGNEE(S): Fresenius Kabi Deutschland GmbH, Germany
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001091713	A1	20011206	WO 2001-EP6058	20010528
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,			

UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

DE 10026998	A1	20011213	DE 2000-10026998	20000531
CA 2409921	AA	20011206	CA 2001-2409921	20010528
AU 2001070540	A5	20011211	AU 2001-70540	20010528
EP 1289492	A1	20030312	EP 2001-949362	20010528

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2001011272	A	20030610	BR 2001-11272	20010528
JP 2003534363	T2	20031118	JP 2001-587729	20010528
NZ 522669	A	20031128	NZ 2001-522669	20010528
NO 2002005604	A	20030122	NO 2002-5604	20021121
US 2004223988	A1	20041111	US 2003-296736	20030714

PRIORITY APPLN. INFO.:	DE 2000-10026998	A	20000531
	WO 2001-EP6058	W	20010528

AB The present invention relates to methods for preparing a **cosmetic** composition comprising HSA, wherein (a) HSA is obtained from a transgenic non-human animal; and (b) HSA is mixed with a suitable carrier and/or adjuvant. According to a preferred embodiment the invention is directed to a method HSA is obtained from the milk of a lactating bovine. Finally, the invention also relates to the **cosmetic** composition obtainable according to these methods as well as their use for **cosmetic** treatment of wrinkles, scars and burn wounds.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L74 ANSWER 19 OF 47 USPATFULL on STN

ACCESSION NUMBER: 2001:229235 USPATFULL

TITLE: METHOD FOR USING SOLUBLE CURCUMIN TO INHIBIT
 PHOSPHORYLASE KINASE IN INFLAMMATORY DISEASES

INVENTOR(S): HENG, MADALENE C.Y., NORTHRIDGE, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001051184	A1	20011213
APPLICATION INFO.:	US 1999-315856	A1	19990520 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ATTN: DAVID A. FARAH. M.D., SHELDON & MAK, 225 SOUTH LAKE AVENUE, SUITE 900, PASADENA, CA, 91101		
NUMBER OF CLAIMS:	115		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Page(s)		
LINE COUNT:	4191		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The compound curcumin, derived from turmeric, inhibits phosphorylase kinase and, by doing so, exhibits a number of physiological effects related to the control of inflammation and cellular proliferation. However, curcumin is effective only when in solution. Curcumin is almost completely insoluble in water or in oils, but is soluble in alcohols. Accordingly, a method for treating inflammation in a mammal comprising administering curcumin in a solution containing at least one alcohol to a mammal to detectably inhibit the activity of phosphorylase kinase in the blood of the mammal or in a tissue of the mammal. The alcohol is preferably ethanol, 1-propanol, or 2-propanol; most preferably, it is ethanol. Instead of curcumin, a curcumin derivative or curcuminoid can be administered. The method can further comprise the administration of at least one additional compound that can be (1) vitamin D.sub.3 and vitamin D.sub.3 analogues; (2) vitamin A, vitamin A derivatives, and vitamin A analogues (3) a calmodulin inhibitor; (4) an anti-inflammatory drug; (5) a calcium channel blocker; (6) a H1 or H2 histamine blocker; (7) an antioxidant; (8) a polyphenolic compound; (9) a monoterpene; (10) genistein; (11) a soybean derived lectin; and (12) dehydrozingerone. Another aspect of the present invention is a pharmaceutical composition

comprising curcumin, a curcuminoid, or a curcumin derivative in a solution containing at least one alcohol, at least one additional compound as described above, and a pharmaceutically acceptable carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 20 OF 47 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 1998-239842 [21] WPIDS
CROSS REFERENCE: 1994-293954 [36]; 1996-159656 [16]; 1997-331543 [30];
1997-332006 [30]; 1997-384623 [35]; 1997-456762 [42];
1997-469491 [43]; 1998-348021 [30]; 1999-095455 [08];
2001-061279 [07]; 2002-075343 [10]; 2003-058783 [05];
2003-401256 [38]; 2003-531847 [50]; 2004-447356 [42]
DOC. NO. CPI: C1998-074814
TITLE: Stabilising a total nutrient admixture composition -
comprising coating submicron oil droplets with
biocompatible polymers and an aqueous medium.
DERWENT CLASS: B05 B07
INVENTOR(S): DESAI, N P; MAGDASSI, S; SOON-SHIONG, P; TAO, C; YANG, A;
YAO, Z
PATENT ASSIGNEE(S): (AMBI-N) AMERICAN BIOSCIENCE INC; (VIVO-N) VIVORX PHARM
INC
COUNTRY COUNT: 79
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9814175	A1	19980409	(199821)*	EN	27
RW:	AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT				
	SD SE SZ UG ZW				
W:	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE				
	GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN				
	MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ				
	VN YU ZW				
AU 9746610	A	19980424	(199835)		
US 5997904	A	19991207	(200004)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9814175	A1	WO 1997-US17649	19970929
AU 9746610	A	AU 1997-46610	19970929
US 5997904	A Div ex	US 1993-23698	19930222
	CIP of	US 1995-412726	19950329
		US 1996-723805	19960930

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9746610	A Based on	WO 9814175
US 5997904	A Div ex	US 5439686
	CIP of	US 5560933

PRIORITY APPLN. INFO: US 1996-723805 19960930; US
1993-23698 19930222; US
1995-412726 19950329

AN 1998-239842 [21] WPIDS
CR 1994-293954 [36]; 1996-159656 [16]; 1997-331543 [30]; 1997-332006 [30];
1997-384623 [35]; 1997-456762 [42]; 1997-469491 [43]; 1998-348021 [30];
1999-095455 [08]; 2001-061279 [07]; 2002-075343 [10]; 2003-058783 [05];
2003-401256 [38]; 2003-531847 [50]; 2004-447356 [42]
AB WO 9814175 A UPAB: 20040920
Stabilising a total nutrient admixture (TNA) composition comprises
subjecting a mixture comprising submicron oil droplets (SOD) stabilised by

coating with biocompatible polymers (BP) and an aqueous medium containing sugars, amino acids and electrolytes and optionally calcium sequestering agents, water, water-soluble vitamins, water-soluble trace elements, stabilisers, therapeutic agents and/or oil-soluble vitamins, to high shear and cavitation forces. Also claimed are: (a) a stabilised TNA composition for in vivo parenteral delivery of a pharmacologically acceptable lipid or fat comprising submicron droplets of lipid or fat stabilised by intimate association with BP, the lipid or fat being solid or liquid and the diameter of the stabilised droplets being at most 10 microns; (b) a method for delivery of TNA to a subject comprising administering the either of the compositions as above.

USE - The TNA is useful for in vivo parenteral delivery of pharmacologically acceptable lipids or fats. **Human serum albumin**, the preferred stabilising agent, gives improved survival when given as a supplement to patients receiving conventional forms of TNAs. The organic media used in the compositions are useful for delivering drugs, and diagnostic agents, as artificial blood and parenteral nutrition agents and in **cosmetic** applications such as **skin** creams or **hair** care products, in perfumery applications and pressure sensitive inks.

ADVANTAGE - The compositions are easily reconstituted with water to form multi-component or three-in-one TNA compositions. The costs associated with the use of TNA compositions are reduced, since the lyophilised powder can be transported and stored for great lengths of time without loss of stability. The 3-in-1 dry powder can be reconstituted with sterile water and injected as a single component into a peripheral vein, even at the patient's home, without the need for a hospital pharmacy. Use of powdered TNA simplifies the preparation procedure and minimises the risk of error and possible contamination.

Dwg.0/0

L74 ANSWER 21 OF 47 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:667258 PROMT
TITLE: In Vitro continued
COLIPA, DGXI conduct joint validation study on in vitro phototoxicity tests
SOURCE: Drug & Cosmetic Industry, (Dec 1996) pp. 8.
ISSN: 0012-6527.
LANGUAGE: English
WORD COUNT: 747

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

AB Phototoxicity is defined as an acute reaction which can be caused by a single treatment with a chemical and UV or visible radiation. In vivo the reaction can be evoked in all subjects provided that the concentration of chemical dose and light are appropriate. The term photoirritation is used to describe phototoxic reactions in skin which are produced with topically applied substances following exposure to light. In 1992, the European **Cosmetic** Toiletry and Perfumery Association (COLIPA) and DGXI of the European Union (EU) agreed to conduct a joint validation project on in vitro phototoxicity tests. The project consists of three phases: phase I validation would be completed in 1994, phase II in 1996 and phase III completion projected for 1997. An update on the EU/COLIPA project was presented by G. Frank Gerberick, PhD, Miami Valley Laboratories, The Procter & Gamble Company at the 5th annual New Technologies Workshop held by Microbiological Associates. The goal of phase I (1992-1993) was to determine if currently selected in vitro methods were capable of properly predicting the photoirritation potential to humans of chemicals applied via the systemic route or topically to the skin. It was designed as a prevalidation study to screen out the most promising in vitro test procedures for a validation trial under blind conditions using both screening and mechanistic tests. Twenty test chemicals were employed (eleven phototoxins, nine non-PT, and four UV absorbing non-PT). These phase I findings showed that the 3T3 neutral red uptake phototoxicity assay provided the highest predictivity of all the in vitro assays evaluated. (Spielmann et al. Curr Probl Dermatol. 1995,

23:256-264.) The purpose of phase II was to confirm the reliability and the relevance of the tests established in order to predict phototoxic effects and to identify photoirritant chemicals. A blind trial was performed following current recommendations of validation studies with eleven laboratories participating nine of whom performed the 3T3 assay. A total of 30 chemicals were tested; six non-phototoxic compounds including PABA, SLS, Penicillin G and 24 phototoxic compounds including 6-Methylcoumarin, Bergamot Oil, Musk Ambrette, Rose Bengal. The methods used for screening purposes were the 3T3 neutral red uptake phototoxicity assay, the SKIN[2TM] phototoxicity assay, the Human Keratinocytes assay and the SOLARTEX-PI[TM] assay.

THIS IS AN EXCERPT: COPYRIGHT 1996 Advanstar Communications Inc.

L74 ANSWER 22 OF 47 USPATFULL on STN

ACCESSION NUMBER: 96:116386 USPATFULL
 TITLE: Acyclovir antiviral gel composition
 INVENTOR(S): Sintov, Amnon, Omer, Israel
 Uzan, Rina, Beer Sheva, Israel
 PATENT ASSIGNEE(S): AGIS Industries (1983) Ltd., Yerucham, Israel (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5585379		19961217
APPLICATION INFO.:	US 1993-186259		19931228 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1992-104283	19921230
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Wilson, James O.	
LEGAL REPRESENTATIVE:	Darby & Darby	
NUMBER OF CLAIMS:	1	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 6 Drawing Page(s)	
LINE COUNT:	759	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An antiviral topical pharmaceutical composition for treating viral diseases of the skin or mucosa comprises a poorly soluble antiviral nucleoside derivative, dispersed in an aqueous gel carrier containing a gelling agent and a water-soluble carboxylic or dicarboxylic acid salt.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 23 OF 47 USPATFULL on STN

ACCESSION NUMBER: 96:113909 USPATFULL
 TITLE: Adhesive sealant composition
 INVENTOR(S): Barrows, Thomas H., Cottage Grove, MN, United States
 Lewis, Terry W., Woodbury, MN, United States
 Truong, Myhanh T., Blaine, MN, United States
 PATENT ASSIGNEE(S): Minnesota Mining and Manufacturing Company, Saint Paul, MN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5583114		19961210
APPLICATION INFO.:	US 1994-281473		19940727 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Weimar, Elizabeth C.		
ASSISTANT EXAMINER:	Mohamed, Abdel A.		
LEGAL REPRESENTATIVE:	Griswold, Gary L., Kirn, Walter N., Busse, Paul W.		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)		

LINE COUNT: 1017

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is related to an adhesive composition which may be used to bond or seal tissue in vivo. The adhesive composition is readily formed from a two component mixture which includes a first part of a protein, preferably a serum albumin protein, in an aqueous buffer having a pH in the range of about 8.0-11.0 and a second part of a water-compatible or water-soluble bifunctional crosslinking agent. When the two parts of the mixture are combined, the mixture is initially a liquid which cures in vivo on the surface of tissue in less than about one minute to give a strong, flexible, pliant substantive composition which bonds to the tissue and is absorbed in about four to sixty days. The adhesive composition may be used either to bond tissue, to seal tissue or to prevent tissue adhesions caused by surgery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L74 ANSWER 24 OF 47 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER: 1995-200996 [27] WPIDS
DOC. NO. CPI: C1995-092959
TITLE: Skin refresher lotion for improving wrinkles.
DERWENT CLASS: B04 D21
INVENTOR(S): SHAN, K
PATENT ASSIGNEE(S): (SHAN-I) SHAN K
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
CN 1085424	A	19940420	(199527)*		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
CN 1085424	A	CN 1993-105601	19930508

PRIORITY APPLN. INFO: CN 1993-105601 19930508

AN 1995-200996 [27] WPIDS

AB CN 1085424 A UPAB: 19950712

A skin-moistening cream or skin-protecting cosmetic, is prepared by mixing alcohol maceration liquid of liquorice root, glycerin, human serum albumin, honey and distilled water.

USE - The compsn. can be used to prevent and treat pachylosis, wrinkles and chapped skin.

L74 ANSWER 25 OF 47 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN

ACCESSION NUMBER: 1990-01481 DRUGU P G

TITLE: Drug Targeting. Colloid Carriers for i.v. Administration - Dream or Realistic Possibility. (Question.).

AUTHOR: Mueller R H; Heinemann S

LOCATION: Kiel, Germany, West

SOURCE: Dtsch. Apoth. Ztg. (129, No. 41, 2188-93, 1989) 6 Fig. 31 Ref. CODEN: DAZE2 ISSN: 0011-9857

AVAIL. OF DOC.: Pharmazeutische Institut Gutenbergstrasse 76-78, 2300 Kiel, West Germany.

LANGUAGE: German

DOCUMENT TYPE: Journal

FIELD AVAIL.: AB; LA; CT

FILE SEGMENT: Literature

AN 1990-01481 DRUGU P G

AB The targeting of drugs such as cytostatics is reviewed with reference to prodrugs, antibody-spacer- drug-conjugates, colloid carriers (including fat emulsions, liposomes, and micro- and nanoparticles), use of colloid

carriers for i.v. targeting, and organ-partitioning of drug carriers including the effect of surface-modification with hydrophilic polymers on organ partitioning.

ABEX Targeting systems dealt with are antibody-drug conjugates (with and without spacers such as **human serum albumin**), fat emulsions (egg lecithin, Lipofundin MCT, Lipovenos and Intralipid), multilamellar, small unilamellar and large unilamellar liposomes (used in **cosmetic skin** products such as Capture), micro- and nanoparticles of polymers including poly lactic acid, copolymers of lactic acid and glycollic acid, polystyrol-latex, cyanoacrylate (used for doxorubicin) and alkyl cyanoacrylates. The properties of particles can be modified by coating with hydrophilic materials including poloxamer-407, poloxamine-908, polyethyleneglycol, polypropylene oxide and this can decrease capture of particles by macrophages, particularly in the liver and spleen. Liposomes present a means of targeting cytostatic drugs such as methotrexate to the liver and spleen, but targeting to other organs is difficult to achieve. Controlled drug release can be achieved by implantation of microsphere preparations such as Zoladex. Use of antimony trisulfide in bone marrow scintigraph is mentioned. (S67/WS) (Drug Targeting. Kolloide Carrier zur Intraveboesen Applikation - Wunschtraum oder realistische Chance.)

L74 ANSWER 26 OF 47 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1988:62268 CAPLUS
DOCUMENT NUMBER: 108:62268
TITLE: Antiwrinkle **cosmetic** composition containing human serum albumin and sodium silicate
INVENTOR(S): Kligman, Albert M.
PATENT ASSIGNEE(S): Exovir, Inc., USA
SOURCE: Eur. Pat. Appl., 5 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 244859	A2	19871111	EP 1987-106617	19870507
EP 244859	A3	19880203		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ZA 8702982	A	19871230	ZA 1987-2982	19870427
IL 82413	A1	19910131	IL 1987-82413	19870503
DK 8702326	A	19871110	DK 1987-2326	19870506
BR 8702330	A	19880217	BR 1987-2330	19870507
AU 8772624	A1	19871112	AU 1987-72624	19870508
AU 599102	B2	19900712		
JP 63022008	A2	19880129	JP 1987-113410	19870509
PRIORITY APPLN. INFO.:			US 1986-861574	A 19860509

AB An aqueous composition containing **human serum albumin** and Na silicate is useful for **cosmetic** purposes for application to facial **skin** to effect smoothing of the **skin** and temporary removal of fine wrinkles. The liquid composition is applied as a coating or film and permitted to dry. Upon drying, the composition lifts the skin up and the fine wrinkles are smoothed out and removed. An antiwrinkle preparation contained human serum albumin 15, Na silicate 5, Fe2O3 and/or TiO2 2, glycerin 1 %, a small amount of preservative, and water to 100%.

L74 ANSWER 27 OF 47 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1986:466259 CAPLUS
DOCUMENT NUMBER: 105:66259
TITLE: Antiwrinkle **cosmetic** preparation
INVENTOR(S): Miller, Daniel G.
PATENT ASSIGNEE(S): Exovir, Inc., USA
SOURCE: Eur. Pat. Appl., 8 pp.

DOCUMENT TYPE: CODEN: EPXXDW
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 180968	A2	19860514	EP 1985-114086	19851105
EP 180968	A3	19870819		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
ZA 8508074	A	19860625	ZA 1985-8074	19851021
AU 8548940	A1	19860515	AU 1985-48940	19851022
AU 582797	B2	19890413		
CA 1260836	A1	19890926	CA 1985-493626	19851023
DK 8505049	A	19860507	DK 1985-5049	19851101
BR 8505477	A	19860805	BR 1985-5477	19851101
JP 61118310	A2	19860605	JP 1985-248669	19851105
ES 548546	A1	19861201	ES 1985-548546	19851105
PRIORITY APPLN. INFO.:			US 1984-668667	A 19841106

AB **Human serum albumin** is useful as an antiwrinkling agent for the smoothing of skin and the temporary removal of fine wrinkles. Thus, an antiwrinkle lotion was prepared by mixing 30% by weight human serum albumin with rose water containing glycerin and preservatives. The lotion was applied to the skin, and dried to form a smooth, homogeneous, and transparent film thereon.

L74 ANSWER 28 OF 47 DGENE COPYRIGHT 2005 The Thomson Corp on STN

ACCESSION NUMBER: ADI26399 protein DGENE

TITLE: Novel fusion polypeptide having epidermal growth factor and human serum albumin linked to C-terminal or N-terminal of epidermal growth factor in which stability of growth factor is enhanced by human serum albumin.

INVENTOR: Lee S; Yoo J; Park S

PATENT ASSIGNEE: (NEXG-N)NEXGEN BIOTECHNOLOGIES INC.

PATENT INFO: WO 2004005340 A1 20040115 57p

APPLICATION INFO: WO 2003-KR1309 20030702

PRIORITY INFO: KR 2002-38165 20020703

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2004-099372 [10]

CROSS REFERENCES: N-PSDB: ADI26398

DESCRIPTION: EGF protein, SEQ ID 2.

AN ADI26399 protein DGENE

AB The invention relates to a fusion polypeptide (I) comprising epidermal growth factor (EGF) and **human serum albumin** linked to the C-terminal or N-terminal of the EGF, and in which the stability of the EGF is enhanced by virtue of the **human serum albumin**. Also disclosed is a **cosmetic** composition for **skin** care, which comprises a fusion polypeptide comprising EGF and **human serum albumin** linked to the C-terminal or N-terminal of the EGF as an active ingredient and a carrier, and a pharmaceutical composition (P1), comprising a fusion polypeptide comprising EGF and **human serum albumin** linked to the C-terminal or N-terminal of the EGF as an active ingredient and a carrier. The fusion polypeptide of the invention is useful for preparing **cosmetic** composition for **skin** care. It has a high stability and purity. The current sequence represents the EGF amino acid sequence.

L74 ANSWER 29 OF 47 DGENE COPYRIGHT 2005 The Thomson Corp on STN

ACCESSION NUMBER: ADI38559 protein DGENE

TITLE: Preparing a fusion polypeptide comprising epidermal growth factor and human serum albumin in a plant comprises transforming plant cells with a polynucleotide sequence that encodes the fusion polypeptide.

INVENTOR: Lee S; Yoo J; Park S
PATENT ASSIGNEE: (NEXG-N)NEXGEN BIOTECHNOLOGIES INC.
PATENT INFO: WO 2004005520 A1 20040115 57p
APPLICATION INFO: WO 2003-KR1310 20030702
PRIORITY INFO: KR 2002-38165 20020703
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2004-091372 [09]
CROSS REFERENCES: N-PSDB: ADI38558
DESCRIPTION: Human epidermal growth factor, EGF, SEQ ID 2.

AN ADI38559 protein DGENE
AB The present invention relates to a method for preparing fusion proteins comprising epidermal growth factor (EGF; ADI38559) and **human serum albumin** in a plant. The method comprising transforming plant cells with a DNA sequence comprising a fusion protein coding sequence, a promoter and a 3'-non-translated region. The **human serum albumin** is linked to the C-terminal of the EGF. The fusion protein is useful for preparing a **cosmetic** composition for **skin** care, and a pharmaceutical composition for treating, e.g. gastric ulcers, neurodegenerative disorders such as Parkinson's disease and wound healing.

L74 ANSWER 30 OF 47 DGENE COPYRIGHT 2005 The Thomson Corp on STN

ACCESSION NUMBER: ADI26398 DNA DGENE
TITLE: Novel fusion polypeptide having epidermal growth factor and human serum albumin linked to C-terminal or N-terminal of epidermal growth factor in which stability of growth factor is enhanced by human serum albumin.

INVENTOR: Lee S; Yoo J; Park S
PATENT ASSIGNEE: (NEXG-N)NEXGEN BIOTECHNOLOGIES INC.
PATENT INFO: WO 2004005340 A1 20040115 57p
APPLICATION INFO: WO 2003-KR1309 20030702
PRIORITY INFO: KR 2002-38165 20020703
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2004-099372 [10]
CROSS REFERENCES: P-PSDB: ADI26399
DESCRIPTION: Synthetically constructed EGF gene, SEQ ID 1.

AN ADI26398 DNA DGENE
AB The invention relates to a fusion polypeptide (I) comprising epidermal growth factor (EGF) and **human serum albumin** linked to the C-terminal or N-terminal of the EGF, and in which the stability of the EGF is enhanced by virtue of the **human serum albumin**. Also disclosed is a **cosmetic** composition for **skin** care, which comprises a fusion polypeptide comprising EGF and **human serum albumin** linked to the C-terminal or N-terminal of the EGF as an active ingredient and a carrier, and a pharmaceutical composition (P1), comprising a fusion polypeptide comprising EGF and **human serum albumin** linked to the C-terminal or N-terminal of the EGF as an active ingredient and a carrier. The fusion polypeptide of the invention is useful for preparing **cosmetic** composition for **skin** care. It has a high stability and purity. The current sequence represents the synthetically constructed EGF gene of the invention.

L74 ANSWER 31 OF 47 DGENE COPYRIGHT 2005 The Thomson Corp on STN

ACCESSION NUMBER: ADI38569 DNA DGENE
TITLE: Preparing a fusion polypeptide comprising epidermal growth factor and human serum albumin in a plant comprises transforming plant cells with a polynucleotide sequence that encodes the fusion polypeptide.

INVENTOR: Lee S; Yoo J; Park S
PATENT ASSIGNEE: (NEXG-N)NEXGEN BIOTECHNOLOGIES INC.
PATENT INFO: WO 2004005520 A1 20040115 57p

APPLICATION INFO: WO 2003-KR1310 20030702
PRIORITY INFO: KR 2002-38165 20020703
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2004-091372 [09]
DESCRIPTION: Albumin-EGF fusion gene PCR primer #2.

AN ADI38569 DNA DGENE

AB The present invention relates to a method for preparing fusion proteins comprising epidermal growth factor (EGF; ADI38559) and **human serum albumin** in a plant. The method comprising transforming plant cells with a DNA sequence comprising a fusion protein coding sequence, a promoter and a 3'-non-translated region. The **human serum albumin** is linked to the C-terminal of the EGF. The fusion protein is useful for preparing a **cosmetic** composition for **skin** care, and a pharmaceutical composition for treating, e.g. gastric ulcers, neurodegenerative disorders such as Parkinson's disease and wound healing. The present sequence is a PCR primer, used in an example from the invention.

L74 ANSWER 32 OF 47 DGENE COPYRIGHT 2005 The Thomson Corp on STN

ACCESSION NUMBER: ADI38566 DNA DGENE

TITLE: Preparing a fusion polypeptide comprising epidermal growth factor and human serum albumin in a plant comprises transforming plant cells with a polynucleotide sequence that encodes the fusion polypeptide.

INVENTOR: Lee S; Yoo J; Park S

PATENT ASSIGNEE: (NEXG-N)NEXGEN BIOTECHNOLOGIES INC.

PATENT INFO: WO 2004005520 A1 20040115 57p

APPLICATION INFO: WO 2003-KR1310 20030702

PRIORITY INFO: KR 2002-38165 20020703

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2004-091372 [09]

DESCRIPTION: Human serum albumin PCR primer #3.

AN ADI38566 DNA DGENE

AB The present invention relates to a method for preparing fusion proteins comprising epidermal growth factor (EGF; ADI38559) and **human serum albumin** in a plant. The method comprising transforming plant cells with a DNA sequence comprising a fusion protein coding sequence, a promoter and a 3'-non-translated region. The **human serum albumin** is linked to the C-terminal of the EGF. The fusion protein is useful for preparing a **cosmetic** composition for **skin** care, and a pharmaceutical composition for treating, e.g. gastric ulcers, neurodegenerative disorders such as Parkinson's disease and wound healing. The present sequence is a PCR primer, used in an example from the invention.

L74 ANSWER 33 OF 47 DGENE COPYRIGHT 2005 The Thomson Corp on STN

ACCESSION NUMBER: ADI38560 DNA DGENE

TITLE: Preparing a fusion polypeptide comprising epidermal growth factor and human serum albumin in a plant comprises transforming plant cells with a polynucleotide sequence that encodes the fusion polypeptide.

INVENTOR: Lee S; Yoo J; Park S

PATENT ASSIGNEE: (NEXG-N)NEXGEN BIOTECHNOLOGIES INC.

PATENT INFO: WO 2004005520 A1 20040115 57p

APPLICATION INFO: WO 2003-KR1310 20030702

PRIORITY INFO: KR 2002-38165 20020703

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2004-091372 [09]

DESCRIPTION: Human epidermal growth factor, EGF, PCR primer #1.

AN ADI38560 DNA DGENE

AB The present invention relates to a method for preparing fusion proteins

comprising epidermal growth factor (EGF; ADI38559) and **human serum albumin** in a plant. The method comprising transforming plant cells with a DNA sequence comprising a fusion protein coding sequence, a promoter and a 3'-non-translated region. The **human serum albumin** is linked to the C-terminal of the EGF. The fusion protein is useful for preparing a **cosmetic** composition for **skin** care, and a pharmaceutical composition for treating, e.g. gastric ulcers, neurodegenerative disorders such as Parkinson's disease and wound healing. The present sequence is a PCR primer, used in an example from the invention.

L74 ANSWER 34 OF 47 DGENE COPYRIGHT 2005 The Thomson Corp on STN

ACCESSION NUMBER: ADI38574 DNA DGENE

TITLE: Preparing a fusion polypeptide comprising epidermal growth factor and human serum albumin in a plant comprises transforming plant cells with a polynucleotide sequence that encodes the fusion polypeptide.

INVENTOR: Lee S; Yoo J; Park S

PATENT ASSIGNEE: (NEXG-N)NEXGEN BIOTECHNOLOGIES INC.

PATENT INFO: WO 2004005520 A1 20040115 57p

APPLICATION INFO: WO 2003-KR1310 20030702

PRIORITY INFO: KR 2002-38165 20020703

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2004-091372 [09]

DESCRIPTION: EGF-Albumin fusion gene PCR primer #1.

AN ADI38574 DNA DGENE

AB The present invention relates to a method for preparing fusion proteins comprising epidermal growth factor (EGF; ADI38559) and **human serum albumin** in a plant. The method comprising transforming plant cells with a DNA sequence comprising a fusion protein coding sequence, a promoter and a 3'-non-translated region. The **human serum albumin** is linked to the C-terminal of the EGF. The fusion protein is useful for preparing a **cosmetic** composition for **skin** care, and a pharmaceutical composition for treating, e.g. gastric ulcers, neurodegenerative disorders such as Parkinson's disease and wound healing. The present sequence is a PCR primer, used in an example from the invention.

L74 ANSWER 35 OF 47 DGENE COPYRIGHT 2005 The Thomson Corp on STN

ACCESSION NUMBER: ADI38561 DNA DGENE

TITLE: Preparing a fusion polypeptide comprising epidermal growth factor and human serum albumin in a plant comprises transforming plant cells with a polynucleotide sequence that encodes the fusion polypeptide.

INVENTOR: Lee S; Yoo J; Park S

PATENT ASSIGNEE: (NEXG-N)NEXGEN BIOTECHNOLOGIES INC.

PATENT INFO: WO 2004005520 A1 20040115 57p

APPLICATION INFO: WO 2003-KR1310 20030702

PRIORITY INFO: KR 2002-38165 20020703

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2004-091372 [09]

DESCRIPTION: Human epidermal growth factor, EGF, PCR primer #2.

AN ADI38561 DNA DGENE

AB The present invention relates to a method for preparing fusion proteins comprising epidermal growth factor (EGF; ADI38559) and **human serum albumin** in a plant. The method comprising transforming plant cells with a DNA sequence comprising a fusion protein coding sequence, a promoter and a 3'-non-translated region. The **human serum albumin** is linked to the C-terminal of the EGF. The fusion protein is useful for preparing a **cosmetic** composition for **skin** care, and a pharmaceutical composition for treating, e.g. gastric ulcers,

neurodegenerative disorders such as Parkinson's disease and wound healing. The present sequence is a PCR primer, used in an example from the invention.

L74 ANSWER 36 OF 47 DGENE COPYRIGHT 2005 The Thomson Corp on STN

ACCESSION NUMBER: ADI38567 DNA DGENE

TITLE: Preparing a fusion polypeptide comprising epidermal growth factor and human serum albumin in a plant comprises transforming plant cells with a polynucleotide sequence that encodes the fusion polypeptide.

INVENTOR: Lee S; Yoo J; Park S

PATENT ASSIGNEE: (NEXG-N)NEXGEN BIOTECHNOLOGIES INC.

PATENT INFO: WO 2004005520 A1 20040115 57p

APPLICATION INFO: WO 2003-KR1310 20030702

PRIORITY INFO: KR 2002-38165 20020703

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2004-091372 [09]

DESCRIPTION: Human serum albumin PCR primer #4.

AN ADI38567 DNA DGENE

AB The present invention relates to a method for preparing fusion proteins comprising epidermal growth factor (EGF; ADI38559) and **human serum albumin** in a plant. The method comprising transforming plant cells with a DNA sequence comprising a fusion protein coding sequence, a promoter and a 3'-non-translated region. The **human serum albumin** is linked to the C-terminal of the EGF. The fusion protein is useful for preparing a **cosmetic** composition for **skin** care, and a pharmaceutical composition for treating, e.g. gastric ulcers, neurodegenerative disorders such as Parkinson's disease and wound healing. The present sequence is a PCR primer, used in an example from the invention.

L74 ANSWER 37 OF 47 DGENE COPYRIGHT 2005 The Thomson Corp on STN

ACCESSION NUMBER: ADI38573 DNA DGENE

TITLE: Preparing a fusion polypeptide comprising epidermal growth factor and human serum albumin in a plant comprises transforming plant cells with a polynucleotide sequence that encodes the fusion polypeptide.

INVENTOR: Lee S; Yoo J; Park S

PATENT ASSIGNEE: (NEXG-N)NEXGEN BIOTECHNOLOGIES INC.

PATENT INFO: WO 2004005520 A1 20040115 57p

APPLICATION INFO: WO 2003-KR1310 20030702

PRIORITY INFO: KR 2002-38165 20020703

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2004-091372 [09]

DESCRIPTION: Albumin-EGF fusion gene PCR primer #6.

AN ADI38573 DNA DGENE

AB The present invention relates to a method for preparing fusion proteins comprising epidermal growth factor (EGF; ADI38559) and **human serum albumin** in a plant. The method comprising transforming plant cells with a DNA sequence comprising a fusion protein coding sequence, a promoter and a 3'-non-translated region. The **human serum albumin** is linked to the C-terminal of the EGF. The fusion protein is useful for preparing a **cosmetic** composition for **skin** care, and a pharmaceutical composition for treating, e.g. gastric ulcers, neurodegenerative disorders such as Parkinson's disease and wound healing. The present sequence is a PCR primer, used in an example from the invention.

L74 ANSWER 38 OF 47 DGENE COPYRIGHT 2005 The Thomson Corp on STN

ACCESSION NUMBER: ADI38562 DNA DGENE

TITLE: Preparing a fusion polypeptide comprising epidermal growth factor and human serum albumin in a plant comprises

transforming plant cells with a polynucleotide sequence that encodes the fusion polypeptide.

INVENTOR: Lee S; Yoo J; Park S
PATENT ASSIGNEE: (NEXG-N)NEXGEN BIOTECHNOLOGIES INC.
PATENT INFO: WO 2004005520 A1 20040115
APPLICATION INFO: WO 2003-KR1310 20030702
PRIORITY INFO: KR 2002-38165 20020703
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2004-091372 [09]
DESCRIPTION: Human serum albumin PCR primer #1.

57p

AN ADI38562 DNA DGENE
AB The present invention relates to a method for preparing fusion proteins comprising epidermal growth factor (EGF; ADI38559) and **human serum albumin** in a plant. The method comprising transforming plant cells with a DNA sequence comprising a fusion protein coding sequence, a promoter and a 3'-non-translated region. The **human serum albumin** is linked to the C-terminal of the EGF. The fusion protein is useful for preparing a **cosmetic** composition for **skin** care, and a pharmaceutical composition for treating, e.g. gastric ulcers, neurodegenerative disorders such as Parkinson's disease and wound healing. The present sequence is a PCR primer, used in an example from the invention.

L74 ANSWER 39 OF 47 DGENE COPYRIGHT 2005 The Thomson Corp on STN

ACCESSION NUMBER: ADI38572 DNA DGENE
TITLE: Preparing a fusion polypeptide comprising epidermal growth factor and human serum albumin in a plant comprises transforming plant cells with a polynucleotide sequence that encodes the fusion polypeptide.

INVENTOR: Lee S; Yoo J; Park S
PATENT ASSIGNEE: (NEXG-N)NEXGEN BIOTECHNOLOGIES INC.
PATENT INFO: WO 2004005520 A1 20040115
APPLICATION INFO: WO 2003-KR1310 20030702
PRIORITY INFO: KR 2002-38165 20020703
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2004-091372 [09]
DESCRIPTION: Albumin-EGF fusion gene PCR primer #5.

57p

AN ADI38572 DNA DGENE
AB The present invention relates to a method for preparing fusion proteins comprising epidermal growth factor (EGF; ADI38559) and **human serum albumin** in a plant. The method comprising transforming plant cells with a DNA sequence comprising a fusion protein coding sequence, a promoter and a 3'-non-translated region. The **human serum albumin** is linked to the C-terminal of the EGF. The fusion protein is useful for preparing a **cosmetic** composition for **skin** care, and a pharmaceutical composition for treating, e.g. gastric ulcers, neurodegenerative disorders such as Parkinson's disease and wound healing. The present sequence is a PCR primer, used in an example from the invention.

L74 ANSWER 40 OF 47 DGENE COPYRIGHT 2005 The Thomson Corp on STN

ACCESSION NUMBER: ADI38570 DNA DGENE
TITLE: Preparing a fusion polypeptide comprising epidermal growth factor and human serum albumin in a plant comprises transforming plant cells with a polynucleotide sequence that encodes the fusion polypeptide.

INVENTOR: Lee S; Yoo J; Park S
PATENT ASSIGNEE: (NEXG-N)NEXGEN BIOTECHNOLOGIES INC.
PATENT INFO: WO 2004005520 A1 20040115
APPLICATION INFO: WO 2003-KR1310 20030702
PRIORITY INFO: KR 2002-38165 20020703
DOCUMENT TYPE: Patent

57p

LANGUAGE: English
OTHER SOURCE: 2004-091372 [09]
DESCRIPTION: Albumin-EGF fusion gene PCR primer #3.
AN ADI38570 DNA DGENE
AB The present invention relates to a method for preparing fusion proteins comprising epidermal growth factor (EGF; ADI38559) and **human serum albumin** in a plant. The method comprising transforming plant cells with a DNA sequence comprising a fusion protein coding sequence, a promoter and a 3'-non-translated region. The **human serum albumin** is linked to the C-terminal of the EGF. The fusion protein is useful for preparing a **cosmetic** composition for **skin** care, and a pharmaceutical composition for treating, e.g. gastric ulcers, neurodegenerative disorders such as Parkinson's disease and wound healing. The present sequence is a PCR primer, used in an example from the invention.

L74 ANSWER 41 OF 47 DGENE COPYRIGHT 2005 The Thomson Corp on STN
ACCESSION NUMBER: ADI38575 DNA DGENE
TITLE: Preparing a fusion polypeptide comprising epidermal growth factor and human serum albumin in a plant comprises transforming plant cells with a polynucleotide sequence that encodes the fusion polypeptide.
INVENTOR: Lee S; Yoo J; Park S
PATENT ASSIGNEE: (NEXG-N)NEXGEN BIOTECHNOLOGIES INC.
PATENT INFO: WO 2004005520 A1 20040115 57p
APPLICATION INFO: WO 2003-KR1310 20030702
PRIORITY INFO: KR 2002-38165 20020703
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2004-091372 [09]
DESCRIPTION: EGF-Albumin fusion gene PCR primer #2.
AN ADI38575 DNA DGENE
AB The present invention relates to a method for preparing fusion proteins comprising epidermal growth factor (EGF; ADI38559) and **human serum albumin** in a plant. The method comprising transforming plant cells with a DNA sequence comprising a fusion protein coding sequence, a promoter and a 3'-non-translated region. The **human serum albumin** is linked to the C-terminal of the EGF. The fusion protein is useful for preparing a **cosmetic** composition for **skin** care, and a pharmaceutical composition for treating, e.g. gastric ulcers, neurodegenerative disorders such as Parkinson's disease and wound healing. The present sequence is a PCR primer, used in an example from the invention.

L74 ANSWER 42 OF 47 DGENE COPYRIGHT 2005 The Thomson Corp on STN
ACCESSION NUMBER: ADI38564 DNA DGENE
TITLE: Preparing a fusion polypeptide comprising epidermal growth factor and human serum albumin in a plant comprises transforming plant cells with a polynucleotide sequence that encodes the fusion polypeptide.
INVENTOR: Lee S; Yoo J; Park S
PATENT ASSIGNEE: (NEXG-N)NEXGEN BIOTECHNOLOGIES INC.
PATENT INFO: WO 2004005520 A1 20040115 57p
APPLICATION INFO: WO 2003-KR1310 20030702
PRIORITY INFO: KR 2002-38165 20020703
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2004-091372 [09]
DESCRIPTION: Human epidermal growth factor, EGF, PCR primer #3.
AN ADI38564 DNA DGENE
AB The present invention relates to a method for preparing fusion proteins comprising epidermal growth factor (EGF; ADI38559) and **human serum albumin** in a plant. The method comprising transforming plant cells with a DNA sequence comprising a fusion protein

coding sequence, a promoter and a 3'-non-translated region. The **human serum albumin** is linked to the C-terminal of the EGF. The fusion protein is useful for preparing a **cosmetic** composition for **skin** care, and a pharmaceutical composition for treating, e.g. gastric ulcers, neurodegenerative disorders such as Parkinson's disease and wound healing. The present sequence is a PCR primer, used in an example from the invention.

L74 ANSWER 43 OF 47 DGENE COPYRIGHT 2005 The Thomson Corp on STN

ACCESSION NUMBER: ADI38563 DNA DGENE

TITLE: Preparing a fusion polypeptide comprising epidermal growth factor and human serum albumin in a plant comprises transforming plant cells with a polynucleotide sequence that encodes the fusion polypeptide.

INVENTOR: Lee S; Yoo J; Park S

PATENT ASSIGNEE: (NEXG-N)NEXGEN BIOTECHNOLOGIES INC.

PATENT INFO: WO 2004005520 A1 20040115 57p

APPLICATION INFO: WO 2003-KR1310 20030702

PRIORITY INFO: KR 2002-38165 20020703

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2004-091372 [09]

DESCRIPTION: Human serum albumin PCR primer #2.

AN ADI38563 DNA DGENE

AB The present invention relates to a method for preparing fusion proteins comprising epidermal growth factor (EGF; ADI38559) and **human serum albumin** in a plant. The method comprising transforming plant cells with a DNA sequence comprising a fusion protein coding sequence, a promoter and a 3'-non-translated region. The **human serum albumin** is linked to the C-terminal of the EGF. The fusion protein is useful for preparing a **cosmetic** composition for **skin** care, and a pharmaceutical composition for treating, e.g. gastric ulcers, neurodegenerative disorders such as Parkinson's disease and wound healing. The present sequence is a PCR primer, used in an example from the invention.

L74 ANSWER 44 OF 47 DGENE COPYRIGHT 2005 The Thomson Corp on STN

ACCESSION NUMBER: ADI38558 DNA DGENE

TITLE: Preparing a fusion polypeptide comprising epidermal growth factor and human serum albumin in a plant comprises transforming plant cells with a polynucleotide sequence that encodes the fusion polypeptide.

INVENTOR: Lee S; Yoo J; Park S

PATENT ASSIGNEE: (NEXG-N)NEXGEN BIOTECHNOLOGIES INC.

PATENT INFO: WO 2004005520 A1 20040115 57p

APPLICATION INFO: WO 2003-KR1310 20030702

PRIORITY INFO: KR 2002-38165 20020703

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2004-091372 [09]

CROSS REFERENCES: P-PSDB: ADI38559

DESCRIPTION: Human epidermal growth factor, EGF, coding sequence, SEQ ID 1.

AN ADI38558 DNA DGENE

AB The present invention relates to a method for preparing fusion proteins comprising epidermal growth factor (EGF; ADI38559) and **human serum albumin** in a plant. The method comprising transforming plant cells with a DNA sequence comprising a fusion protein coding sequence, a promoter and a 3'-non-translated region. The **human serum albumin** is linked to the C-terminal of the EGF. The fusion protein is useful for preparing a **cosmetic** composition for **skin** care, and a pharmaceutical composition for treating, e.g. gastric ulcers, neurodegenerative disorders such as Parkinson's disease and wound

healing. The present sequence is the coding sequence for human EGF.

L74 ANSWER 45 OF 47 DGENE COPYRIGHT 2005 The Thomson Corp on STN

ACCESSION NUMBER: ADI38565 DNA DGENE

TITLE: Preparing a fusion polypeptide comprising epidermal growth factor and human serum albumin in a plant comprises transforming plant cells with a polynucleotide sequence that encodes the fusion polypeptide.

INVENTOR: Lee S; Yoo J; Park S

PATENT ASSIGNEE: (NEXG-N)NEXGEN BIOTECHNOLOGIES INC.

PATENT INFO: WO 2004005520 A1 20040115 57p

APPLICATION INFO: WO 2003-KR1310 20030702

PRIORITY INFO: KR 2002-38165 20020703

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2004-091372 [09]

DESCRIPTION: Human epidermal growth factor, EGF, PCR primer #4.

AN ADI38565 DNA DGENE

AB The present invention relates to a method for preparing fusion proteins comprising epidermal growth factor (EGF; ADI38559) and **human serum albumin** in a plant. The method comprising transforming plant cells with a DNA sequence comprising a fusion protein coding sequence, a promoter and a 3'-non-translated region. The **human serum albumin** is linked to the C-terminal of the EGF. The fusion protein is useful for preparing a **cosmetic** composition for **skin** care, and a pharmaceutical composition for treating, e.g. gastric ulcers, neurodegenerative disorders such as Parkinson's disease and wound healing. The present sequence is a PCR primer, used in an example from the invention.

L74 ANSWER 46 OF 47 DGENE COPYRIGHT 2005 The Thomson Corp on STN

ACCESSION NUMBER: ADI38568 DNA DGENE

TITLE: Preparing a fusion polypeptide comprising epidermal growth factor and human serum albumin in a plant comprises transforming plant cells with a polynucleotide sequence that encodes the fusion polypeptide.

INVENTOR: Lee S; Yoo J; Park S

PATENT ASSIGNEE: (NEXG-N)NEXGEN BIOTECHNOLOGIES INC.

PATENT INFO: WO 2004005520 A1 20040115 57p

APPLICATION INFO: WO 2003-KR1310 20030702

PRIORITY INFO: KR 2002-38165 20020703

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2004-091372 [09]

DESCRIPTION: Albumin-EGF fusion gene PCR primer #1.

AN ADI38568 DNA DGENE

AB The present invention relates to a method for preparing fusion proteins comprising epidermal growth factor (EGF; ADI38559) and **human serum albumin** in a plant. The method comprising transforming plant cells with a DNA sequence comprising a fusion protein coding sequence, a promoter and a 3'-non-translated region. The **human serum albumin** is linked to the C-terminal of the EGF. The fusion protein is useful for preparing a **cosmetic** composition for **skin** care, and a pharmaceutical composition for treating, e.g. gastric ulcers, neurodegenerative disorders such as Parkinson's disease and wound healing. The present sequence is a PCR primer, used in an example from the invention.

L74 ANSWER 47 OF 47 DGENE COPYRIGHT 2005 The Thomson Corp on STN

ACCESSION NUMBER: ADI38571 DNA DGENE

TITLE: Preparing a fusion polypeptide comprising epidermal growth factor and human serum albumin in a plant comprises transforming plant cells with a polynucleotide sequence that encodes the fusion polypeptide.

INVENTOR: Lee S; Yoo J; Park S
PATENT ASSIGNEE: (NEXG-N)NEXGEN BIOTECHNOLOGIES INC.
PATENT INFO: WO 2004005520 A1 20040115 57p
APPLICATION INFO: WO 2003-KR1310 20030702
PRIORITY INFO: KR 2002-38165 20020703
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2004-091372 [09]
DESCRIPTION: Albumin-EGF fusion gene PCR primer #4.

AN ADI38571 DNA DGENE

AB The present invention relates to a method for preparing fusion proteins comprising epidermal growth factor (EGF; ADI38559) and **human serum albumin** in a plant. The method comprising transforming plant cells with a DNA sequence comprising a fusion protein coding sequence, a promoter and a 3'-non-translated region. The **human serum albumin** is linked to the C-terminal of the EGF. The fusion protein is useful for preparing a **cosmetic** composition for **skin** care, and a pharmaceutical composition for treating, e.g. gastric ulcers, neurodegenerative disorders such as Parkinson's disease and wound healing. The present sequence is a PCR primer, used in an example from the invention.

=>

WEST Search History

[Hide Items](#)
[Restore](#)
[Clear](#)
[Cancel](#)

DATE: Wednesday, January 19, 2005

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,EPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L10	(skin or hair) same (human adj serum adj albumin) and cosmetic?	6
<input type="checkbox"/>	L9	(skin or hair) and (human adj serum adj albumin) same cosmetic?	1
<input type="checkbox"/>	L8	(skin or hair) and (human adj serum adj albumin) and cosmetic?	89
<input type="checkbox"/>	L7	(skin or hair) same (human adj (albumin or albumen)) and cosmetic?	2
<input type="checkbox"/>	L6	(skin or hair) same (human adj (albumin or albumen)) and cosmetic	0
<input type="checkbox"/>	L5	(skin or hair) same (human adj (albumin or albumen)) and clean\$	4
<input type="checkbox"/>	L4	(skin or hair) same (human adj (albumin or albumen)) same clean\$	1
<input type="checkbox"/>	L3	(skin or hair) same human adj (albumin or albumen) same clean\$	1
<input type="checkbox"/>	L2	(skin or hair) same human same (albumin or albumen) same (shampoo? or cream? or lotion?)	12
<input type="checkbox"/>	L1	(skin or hair) same human same serum same (albumin or albumen) same (shampoo? or cream? or lotion?)	10

END OF SEARCH HISTORY

Hit List

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Search Results - Record(s) 1 through 6 of 6 returned.

☐ 1. Document ID: US 20040142047 A1

Using default format because multiple data bases are involved.

L10: Entry 1 of 6

File: PGPB

Jul 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040142047

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040142047 A1

TITLE: Korean acanthopanax senticosus extract, protein extract, crude protein-polysaccharide which were extracted from korean acanthopanax senticosus, and immunoregulating compositions comprising the same and use thereof

PUBLICATION-DATE: July 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Yoon, Taek-Joon	Kyungki-do		KR	
Lee, Kyeong-Ho	Kyungki-do		KR	
Park, Woo-Moon	Seoul		KR	
Kim, Youn-Chul	Kyungki-do		KR	
Park, Ho-Jin	Kyungki-do		KR	

US-CL-CURRENT: 424/728; 514/8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-------

☐ 2. Document ID: US 20020123031 A1

L10: Entry 2 of 6

File: PGPB

Sep 5, 2002

PGPUB-DOCUMENT-NUMBER: 20020123031

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020123031 A1

TITLE: METHODS OF USE OF COMPOUNDS WHICH INHIBIT THE STEM CELL SIGNALING PATHWAY

PUBLICATION-DATE: September 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
LONGLEY, B. JACK	HAMDEN	CT	US	

US-CL-CURRENT: 435/4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 3. Document ID: US 20020006892 A1

L10: Entry 3 of 6

File: PGPB

Jan 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020006892

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020006892 A1

TITLE: Serum albumin compositions for use in cleansing or dermatological products for skin or hair

PUBLICATION-DATE: January 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Carter, Daniel C.	Madison	AL	US	

US-CL-CURRENT: 512/12; 424/70.1, 530/363

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 4. Document ID: US 5254331 A

L10: Entry 4 of 6

File: USPT

Oct 19, 1993

US-PAT-NO: 5254331

DOCUMENT-IDENTIFIER: US 5254331 A

TITLE: Skin cream composition

DATE-ISSUED: October 19, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mausner; Jack	New York	NY		

US-CL-CURRENT: 424/59; 424/401, 424/765, 424/769, 514/773, 514/776, 514/777, 514/783, 514/844, 514/847

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 5. Document ID: US 5047249 A

L10: Entry 5 of 6

File: USPT

Sep 10, 1991

US-PAT-NO: 5047249

DOCUMENT-IDENTIFIER: US 5047249 A

TITLE: Compositions and methods for treating skin conditions and promoting wound healing

DATE-ISSUED: September 10, 1991

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rothman; John	Lebanon	NJ		
Band; Philip A.	Brooklyn	NY		

US-CL-CURRENT: 424/543; 424/529, 424/530, 514/2, 514/21, 514/842, 514/859, 514/861, 514/863, 514/886, 514/887

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 6. Document ID: CN 1383811 A

L10: Entry 6 of 6

File: DWPI

Dec 11, 2002

DERWENT-ACC-NO: 2003-334169

DERWENT-WEEK: 200332

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Wrinkle-eliminating cosmetics are prepared with type-A botulinus toxin, azone and physiological saline, vitamin E, alpha-AHAs, SOD as well as protector and human serum albumin

INVENTOR: LU, W; SHENG, Q

PRIORITY-DATA: 2002CN-0111695 (May 16, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
CN 1383811 A	December 11, 2002		000	A61K007/48

INT-CL (IPC): A61 K 7/48

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Term	Documents
SKIN	367337
SKINS	22855
HAIR	121712
HAIRS	15889
HUMAN	634452
HUMANS	159041
SERUM	163973

SERUMS	2006
ALBUMIN	86957
ALBUMINS	4154
((SKIN OR HAIR) SAME (HUMAN ADJ SERUM ADJ ALBUMIN) AND COSMETIC?).PGPB,USPT,EPAB,DWPI,TDBD.	6

[There are more results than shown above. Click here to view the entire set.](#)

Display Format: [Change Format](#)

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Search Results - Record(s) 1 through 4 of 4 returned.

☐ 1. Document ID: US 20020006892 A1

Using default format because multiple data bases are involved.

L5: Entry 1 of 4

File: PGPB

Jan 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020006892

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020006892 A1

TITLE: Serum albumin compositions for use in cleansing or dermatological products for skin or hair

PUBLICATION-DATE: January 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Carter, Daniel C.	Madison	AL	US	

US-CL-CURRENT: 512/12; 424/70.1, 530/363

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 2. Document ID: US 5713891 A

L5: Entry 2 of 4

File: USPT

Feb 3, 1998

US-PAT-NO: 5713891

DOCUMENT-IDENTIFIER: US 5713891 A

TITLE: Modified solder for delivery of bioactive substances and methods of use thereof

DATE-ISSUED: February 3, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Poppas; Dix P.	Brookline	MA		

US-CL-CURRENT: 606/2; 606/213, 606/214, 606/8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 3. Document ID: US 4828561 A

L5: Entry 3 of 4

File: USPT

May 9, 1989

US-PAT-NO: 4828561

DOCUMENT-IDENTIFIER: US 4828561 A

TITLE: Bio compatible and blood compatible materials and methods

DATE-ISSUED: May 9, 1989

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Woodroof; E. Aubrey	Santa Ana	CA		

US-CL-CURRENT: 623/8; 106/153.1, 424/422, 424/445, 427/2.24, 427/2.25, 427/2.3, 427/2.31,
525/474, 602/48, 602/900

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 4. Document ID: US 4820302 A

L5: Entry 4 of 4

File: USPT

Apr 11, 1989

US-PAT-NO: 4820302

DOCUMENT-IDENTIFIER: US 4820302 A

**** See image for Certificate of Correction ****

TITLE: Bio compatible and blood compatible materials and methods

DATE-ISSUED: April 11, 1989

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Woodroof; E. Aubrey	Santa Ana	CA		

US-CL-CURRENT: 623/8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Term	Documents
SKIN	367337
SKINS	22855
HAIR	121712
HAIRS	15889
HUMAN	634452
HUMANS	159041

ALBUMIN	86957
ALBUMINS	4154
ALBUMEN	4791
ALBUMAN	20
ALBUMENS	118
((SKIN OR HAIR) SAME (HUMAN ADJ (ALBUMIN OR ALBUMEN)) AND CLEANS\$.PGPB,USPT,EPAB,DWPI,TDBD.	4

[There are more results than shown above. Click here to view the entire set.](#)

Display Format: [Change Format](#)

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 20040223988 A1

Using default format because multiple data bases are involved.

L7: Entry 1 of 2

File: PGPB

Nov 11, 2004

PGPUB-DOCUMENT-NUMBER: 20040223988

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040223988 A1

TITLE: Cosmetic composition comprising human serum albumin obtained from transgenic non-human animals

PUBLICATION-DATE: November 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Eichner, Wolfram	Butzbach		DE	
Sommermeyer, Klaus	Rosbach		DE	

US-CL-CURRENT: [424/401](#); [514/12](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	----------------------	---------------------------	-----------------------

☐ 2. Document ID: US 20020006892 A1

L7: Entry 2 of 2

File: PGPB

Jan 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020006892

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020006892 A1

TITLE: Serum albumin compositions for use in cleansing or dermatological products for skin or hair

PUBLICATION-DATE: January 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Carter, Daniel C.	Madison	AL	US	

US-CL-CURRENT: [512/12](#); [424/70.1](#), [530/363](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	----------------------	---------------------------	-----------------------

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Term	Documents
SKIN	367337
SKINS	22855
HAIR	121712
HAIRS	15889
HUMAN	634452
HUMANS	159041
ALBUMIN	86957
ALBUMINS	4154
ALBUMEN	4791
ALBUMAN	20
ALBUMENS	118
((SKIN OR HAIR) SAME (HUMAN ADJ (ALBUMIN OR ALBUMEN)) AND COSMETIC?).PGPB,USPT,EPAB,DWPI,TDBD.	2

[There are more results than shown above. Click here to view the entire set.](#)

Display Format:

[Change Format](#)[Previous Page](#)[Next Page](#)[Go to Doc#](#)

Hit List

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#) [Generate OACS](#)

Search Results - Record(s) 1 through 12 of 12 returned.

☐ 1. Document ID: US 20020006892 A1

Using default format because multiple data bases are involved.

L2: Entry 1 of 12

File: PGPB

Jan 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020006892

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020006892 A1

TITLE: Serum albumin compositions for use in cleansing or dermatological products for skin or hair

PUBLICATION-DATE: January 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Carter, Daniel C.	Madison	AL	US	

US-CL-CURRENT: [512/12](#); [424/70.1](#), [530/363](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	NMC	Draw Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	---------------------	---------------------------	-----------------------

☐ 2. Document ID: US 6551607 B1

L2: Entry 2 of 12

File: USPT

Apr 22, 2003

US-PAT-NO: 6551607

DOCUMENT-IDENTIFIER: US 6551607 B1

**** See image for [Certificate of Correction](#) ****

TITLE: Method for sequestration of skin irritants with substrate compositions

DATE-ISSUED: April 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Minerath, III; Bernard Joseph	Oshkosh	WI		
Otts; David Roland	Appleton	WI		
Huard; Linda Susan	Appleton	WI		
Tyrrell; David John	Appleton	WI		
DiLuccio; Robert Cosmo	Alpharetta	GA		
Akin; Frank Jerrel	Marietta	GA		
Buhrow; Chantel Spring	Weyauwega	WI		

Everhart; Dennis Stein	Alpharetta	GA
Nelson; Brenda Marie	Appleton	WI
Shanklin; Gary Lee	Appleton	WI

US-CL-CURRENT: [424/402](#); [424/400](#), [424/401](#), [424/443](#), [424/78.08](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-------

☐ 3. Document ID: US 6534309 B1

L2: Entry 3 of 12

File: USPT

Mar 18, 2003

US-PAT-NO: 6534309

DOCUMENT-IDENTIFIER: US 6534309 B1

**** See image for Certificate of Correction ****

TITLE: Motor proteins and methods for their use

DATE-ISSUED: March 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beraud; Christophe	San Francisco	CA		
Freedman; Richard	San Mateo	CA		

US-CL-CURRENT: [435/320.1](#); [435/183](#), [435/189](#), [435/252.3](#), [435/254.11](#), [435/257.2](#), [435/325](#), [536/23.2](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-------

☐ 4. Document ID: US 6521242 B1

L2: Entry 4 of 12

File: USPT

Feb 18, 2003

US-PAT-NO: 6521242

DOCUMENT-IDENTIFIER: US 6521242 B1

TITLE: Method for sequestration of nasal secretion skin irritants with facial tissue

DATE-ISSUED: February 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Minerath, III; Bernard Joseph	Oshkosh	WI		
Nelson; Brenda Marie	Appleton	WI		
Otts; David Roland	Appleton	WI		
Huard; Linda Susan	Appleton	WI		
Tyrrell; David John	Appleton	WI		
Shanklin; Gary Lee	Appleton	WI		

US-CL-CURRENT: [424/402](#); [424/400](#), [424/401](#), [424/78.08](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 5. Document ID: US 6521241 B1

L2: Entry 5 of 12

File: USPT

Feb 18, 2003

US-PAT-NO: 6521241

DOCUMENT-IDENTIFIER: US 6521241 B1

TITLE: Substrate composition for sequestration of skin irritants

DATE-ISSUED: February 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Minerath, III; Bernard Joseph	Oshkosh	WI		
Otts; David Roland	Appleton	WI		
Huard; Linda Susan	Appleton	WI		
Tyrrell; David John	Appleton	WI		
DiLuccio; Robert Cosmo	Alpharetta	GA		
Akin; Frank Jerrel	Marietta	GA		
Buhrow; Chantel Spring	Weyauwega	WI		
Everhart; Dennis Stein	Alpharetta	GA		
Nelson; Brenda Marie	Appleton	WI		
Shanklin; Gary Lee	Appleton	WI		

US-CL-CURRENT: [424/402](#); [424/400](#), [424/401](#), [424/443](#), [424/78.08](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 6. Document ID: US 6521240 B1

L2: Entry 6 of 12

File: USPT

Feb 18, 2003

US-PAT-NO: 6521240

DOCUMENT-IDENTIFIER: US 6521240 B1

TITLE: Facial tissue composition for sequestration of nasal secretion skin irritants

DATE-ISSUED: February 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Minerath, III; Bernard Joseph	Oshkosh	WI		
Nelson; Brenda Marie	Appleton	WI		
Otts; David Roland	Appleton	WI		
Huard; Linda Susan	Appleton	WI		

Tyrrell; David John Appleton WI
Shanklin; Gary Lee Appleton WI

US-CL-CURRENT: 424/402; 424/400, 424/401, 424/443, 424/78.08

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-------

☐ 7. Document ID: US 6492151 B1

L2: Entry 7 of 12

File: USPT

Dec 10, 2002

US-PAT-NO: 6492151

DOCUMENT-IDENTIFIER: US 6492151 B1

TITLE: Motor proteins and methods for their use

DATE-ISSUED: December 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beraud; Christophe	San Francisco	CA		
Freedman; Richard	San Mateo	CA		

US-CL-CURRENT: 435/183; 435/7.6, 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-------

☐ 8. Document ID: US 6391601 B1

L2: Entry 8 of 12

File: USPT

May 21, 2002

US-PAT-NO: 6391601

DOCUMENT-IDENTIFIER: US 6391601 B1

TITLE: Motor proteins and methods for their use

DATE-ISSUED: May 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beraud; Christophe	San Francisco	CA		
Freedman; Richard	San Mateo	CA		

US-CL-CURRENT: 435/183; 424/130.1, 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-------

☐ 9. Document ID: US 6284536 B1

L2: Entry 9 of 12

File: USPT

Sep 4, 2001

US-PAT-NO: 6284536

DOCUMENT-IDENTIFIER: US 6284536 B1

**** See image for Certificate of Correction ****

TITLE: Modified immunoglobulin molecules and methods for use thereof

DATE-ISSUED: September 4, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Morrison; Sherie L.	Los Angeles	CA		
Chintalacharuvu; Koteswara R.	Los Angeles	CA		
Yoo; Esther Mikyung	Thousand Oaks	CA		
Trinh; Kham M.	Monterey Park	CA		
Coloma; M. Josefina	Santa Monica	CA		

US-CL-CURRENT: 435/328; 424/133.1, 424/160.1, 424/161.1, 435/320.1, 435/339.1, 435/5, 435/69.7, 435/7.1, 435/70.1, 530/387.3, 536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-------

☐ 10. Document ID: US 5047337 A

L2: Entry 10 of 12

File: USPT

Sep 10, 1991

US-PAT-NO: 5047337

DOCUMENT-IDENTIFIER: US 5047337 A

TITLE: Ceramide-glycanase

DATE-ISSUED: September 10, 1991

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Li; Su-Chen	New Orleans	LA	70112	
Li; Yu-Teh	New Orleans	LA	70112	

US-CL-CURRENT: 435/101; 435/129, 435/134, 435/200

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-------

☐ 11. Document ID: JP 2000063227 A

L2: Entry 11 of 12

File: DWPI

Feb 29, 2000

DERWENT-ACC-NO: 2000-342399

DERWENT-WEEK: 200031

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Topical preparation for slimming comprises lipid decomposition promoter comprising one or more kind of vegetable extracts like apricot kennel, cornus officinalis etc

PRIORITY-DATA: 1998JP-0250422 (August 20, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2000063227 A	February 29, 2000		017	A61K007/00

INT-CL (IPC): A61 K 7/00; A61 K 35/78; A61 K 35/84

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 12. Document ID: WO 9814175 A1, AU 9746610 A, US 5997904 A

L2: Entry 12 of 12

File: DWPI

Apr 9, 1998

DERWENT-ACC-NO: 1998-239842

DERWENT-WEEK: 200460

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Stabilising a total nutrient admixture composition - comprising coating submicron oil droplets with biocompatible polymers and an aqueous medium

INVENTOR: DESAI, N P; MAGDASSI, S ; SOON-SHIONG, P ; TAO, C ; YANG, A ; YAO, Z

PRIORITY-DATA: 1996US-0723805 (September 30, 1996), 1993US-0023698 (February 22, 1993), 1995US-0412726 (March 29, 1995)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9814175 A1	April 9, 1998	E	027	A61K009/14
AU 9746610 A	April 24, 1998		000	
US 5997904 A	December 7, 1999		000	

INT-CL (IPC): A61 K 9/14

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Term	Documents
SKIN	367337
SKINS	22855
HAIR	121712
HAIRS	15889
HUMAN	634452
HUMANS	159041

ALBUMIN	86957
ALBUMINS	4154
ALBUMEN	4791
ALBUMAN	20
((SKIN OR HAIR) SAME HUMAN SAME (ALBUMIN OR ALBUMEN) SAME (SHAMPOO? OR CREAM? OR LOTION?)).PGPB,USPT,EPAB,DWPI,TDBD.	12

[There are more results than shown above. Click here to view the entire set.](#)

Display Format: **Change Format**

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)